Page 40 - பல்கலைக்கழகம் ஆஃப் ஜார்ஜ்டவுன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

. The rESPECT IST (NCT04292743) is a single arm, dose escalating Phase 1 clinical trial to evaluate the safety of eryaspase in combination with modified FOLFIRINOX. The trial is conducted by Dr Marcus Noel, Associate Professor of Medicine at Georgetown University, Washington DC, USA, and will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer. FOLFIRINOX is one of the most commonly utilized first-line chemotherapy regimens for the treatment of pancreatic cancer, despite its toxicity. The trial was launched at the end of last year and has now enrolled the first cohort of three patients. After review of the safety data, the Dose Escalation Committee concluded that no dose-limiting toxicity (DLT) had been observed in the first cohort treated at a therapeutic dose of 75 U/kg eryaspase, and as of the date of this press release, treatment was observed to be well tolerated in the cohort.

United statesUnited kingdomFrance generalNew jerseyGeorgetown universityDistrict of columbiaMarcus noelNicolas merigeauEnregistrement universelPharma bioImane hariryMathilde bohinCorey davisLouis victor delouvrierEric soyerLifesci advisors